Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Ris-Rez improves survival in patients with relapsed small-cell lung cancer

14

Sep 2026

Ris-Rez improves survival in patients with relapsed small-cell lung cancer

Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy.

European registry shows continued improvements in cataract surgery outcomes

14

Sep 2026

European registry shows continued improvements in cataract surgery outcomes

A total of 363,039 cataract surgeries performed in 12 European countries in 2024 have been recorded in the European Registry of Quality Outcomes for Cataract and Refractive Surgery (EUREQUO), according to the latest figures presented at the 44th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) today (Tuesday).

An 8-hour eating window stood out for weight loss, but the full picture is more complicated

14

Sep 2026

An 8-hour eating window stood out for weight loss, but the full picture is more complicated

A pooled analysis of individual data from five time-restricted eating trials involving 124 adults linked shorter eating windows with modestly greater weight loss. Eight-hour TRE was associated with greater weight loss than 12-hour TRE and controls, while cardiometabolic outcomes showed no consistent relationship with eating-window duration and several weight associations weakened after adjustment.

More hospitals are adopting AI, yet the access gap is proving hard to close

14

Sep 2026

More hospitals are adopting AI, yet the access gap is proving hard to close

A national analysis of 6,166 US hospitals found that specific workflow AI capabilities were associated with higher sepsis bundle completion rates and lower 30-day pneumonia mortality, whereas robotics showed narrower procedural associations. Geographic access remained highly uneven, with about 114.6 million people in the access-analysis population living more than 30 minutes from an AI-enabled hospital, although the observational design prevents causal conclusions.

Like your tea or coffee very hot? A study of nearly 1 million adults found a striking cancer link

14

Sep 2026

Like your tea or coffee very hot? A study of nearly 1 million adults found a striking cancer link

In pooled prospective data from 977,282 UK adults, preferring tea or coffee “very hot” was associated with more than threefold higher risk of esophageal squamous cell carcinoma compared with preferring drinks “warm,” while drink temperature showed no material association with adenocarcinoma risk. Consuming six or more hot drinks daily was independently associated with higher squamous cell carcinoma risk, and modeling estimated that about 440 UK cases each year could be prevented by switching from “very hot” to “hot” drinks if the association is causal.

What happens to blood pressure during extreme heat? A 4.2 million-visit study offers a clue

14

Sep 2026

What happens to blood pressure during extreme heat? A 4.2 million-visit study offers a clue

In a cross-sectional analysis of more than 4.2 million summer outpatient encounters across US community health centers, same-day extreme heat was associated with small reductions in systolic and diastolic blood pressure, with somewhat larger differences among adults aged 65 years or older. The changes were unlikely to be clinically meaningful for most individuals, suggesting that acute blood pressure shifts may account for little of the cardiovascular risk associated with extreme heat.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.